衰弱与生物标志物确诊阿尔茨海默病的预后:瑞典登记回顾性队列研究
该瑞典登记回顾性队列纳入7251例脑脊液生物标志物支持阿尔茨海默病理的轻度认知障碍或痴呆患者,构建41项衰弱指数。衰弱与基线MMSE较低相关,但不影响MMSE下降速率;衰弱预测机构入住和死亡风险升高。
要点
- 衰弱与基线MMSE较低相关,但与MMSE下降速率无关。
核心结论
- 衰弱指数可预测阿尔茨海默病患者的机构入住和死亡,但与认知下降无关,提示神经退行性变是认知下降的主要驱动因素。
主要发现
- 脑脊液生物标志物与MMSE轨迹的关联未因衰弱状态而异。
关键数值与推荐
- 衰弱指数由41个项目构成,涵盖疾病、症状、多重用药、营养状态和照护依赖。
临床怎么用
- 在生物标志物确诊的阿尔茨海默病患者中,可用衰弱指数评估机构入住和死亡风险,但衰弱不预测认知下降速率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to examine the value of frailty status (defined by the frailty index) in informing the prognosis of people living with Alzheimer's disease. METHODS: In this retrospective cohort study, we used the Swedish Registry for Cognitive/Dementia Disorders linked to other Swedish health-care registers to collect data from May 1, 2007, to Dec 31, 2020. We included people with mild cognitive impairment or Alzheimer's disease dementia, both with cerebrospinal fluid (CSF) biomarkers supporting Alzheimer's pathology. We excluded people living in an institution or those who did not have at least one Mini-Mental State Examination (MMSE). We constructed a 41-item frailty index, incorporating diseases, symptoms, polypharmacy, nutritional status, and care dependency. Individuals with frailty index scores of 0·25 or above were considered frail. The associations between frailty and MMSE trajectories, subsequent institutionalisation, and mortality were evaluated by jointly modelling longitudinal and survival data. We also examined whether frailty could modify the associations between CSF amyloid β42, phosphorylated tau181, and total tau and cognitive decline. FINDINGS: The study included 7251 individuals (mean age 72·7 years, 4271 [58·9%] females, 2980 [41·1%] males). Frailty was associated with a 0·723-point (95% CI 0·250-1·196) lower baseline MMSE but not with the rate of MMSE decline. Frailty was associated with a hazard ratio of 1·91 (1·43-2·54) for institutionalisation and 2·41 (1·73-3·33) for mortality. Individuals living with frailty had a 1·3-year (0·9-1·7) shorter lifespan and a 1·0-year (0·8-1·3) shorter non-institutionalised lifespan. Associations between CSF biomarkers and MMSE trajectories did not differ by frailty status. INTERPRETATION: Frailty, measured by the frailty index, predicted institutionalisation and mortality in people with Alzheimer's disease, but its absence of association with cognitive decline suggests neurodegeneration as the primary driver. FUNDING: Innovative Health Initiative Joint Undertaking and Vinnova.
引用
- Xia X, Eriksdotter M, Zetterberg H, et al. Frailty and prognosis of biomarker-confirmed Alzheimer's disease: a Swedish, register-based, retrospective cohort study. Lancet Healthy Longev. 2025. PMID: 41421376. doi:10.1016/j.lanhl.2025.100797
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。